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Abstract
Purpose: To evaluate the efficacy and toxicity of stereotactic fractionated radiotherapy (SFRT) for patients with
pituitary macroadenoma (PMA).
Methods and Materials: Between March 2000 and March 2009, 27 patients (male to female ratio, 1.25) with PMA
underwent SFRT (median dose, 50.4 Gy). Mean age of the patients was 56.5 years (range, 20.3 - 77.4). In all but one
patient, SFRT was administered for salvage treatment after surgical resection (transphenoidal resection in 23,
transphenoidal resection followed by craniotomy in 2 and multiple transphenoidal resections in another patient). In
10 (37%) patients, the PMAs were functional (3 ACTH-secreting, 3 prolactinomas, 2 growth hormone-secreting and
2 multiple hormone-secretion). Three (11.1%) and 9 (33.3%) patients had PMA abutting and compressing the optic
chiasm, respectively. Mean tumor volume was 2.9 ± 4.6 cm
3. Eighteen (66.7%) patients had hypopituitarism prior to
SFRT. The mean follow-up period after SFRT was 72.4 ± 37.2 months.
Results: Tumor size decreased for 6 (22.2%) patients and remained unchanged for 19 (70.4%) other patients. Two
(7.4%) patients had tumor growth inside the prescribed treatment volume. The estimated 5-year tumor growth
control was 95.5% after SFRT. Biochemical remission occurred in 3 (30%) patients with functional PMA. Two
patients with normal anterior pituitary function before SFRT developed new deficits 25 and 65 months after
treatment. The 5-year survival without new anterior pituitary deficit was thus 95.8%. Five patients with visual field
defect had improved visual function and 1 patient with no visual defect prior to SFRT, but an optic chiasm
abutting tumor, had a decline in visual function. The estimated 5-year vision and pituitary function preservation
rates were 93.2% and 95.8%, respectively.
Conclusions: SFRT is a safe and effective treatment for patients with PMA, although longer follow-up is needed to
evaluate long-term outcomes. In this study, approximately 1 patient with visual field defect out of two had an
improved visual function.
Introduction
Pituitary adenomas are usually benign tumors that
account for 10 - 15% of primary intracranial neoplasms
[1]. Tumor growth frequently causes compression of the
visual apparatus, pituitary stalk, floor of the third ventri-
cle and enlargement of the sella turcica[2,3]. Pituitary
macroadenoma (PMA) refers to tumors more than 10
mm in diameter, although this cutoff is not consensual
[4]. Although debulking surgery is indeed beneficial in a
substantial number of PMA patients, long term tumor
and endocrinological control remains more often than
not elusive, as a result of the tumor extension, superiorly
into the suprasellar cistern and/or laterally in the caver-
nous sinus. Complete resection is achievable in only 44 -
84% of patients with PMA[5]. As such, postoperative
[6,7], salvage[8] or radical radiation therapy (RT) is fre-
quently administered to patients with pituitary tumors in
general, and to PMA patients in particular. RT has been
proven to be an effective treatment in retrospective series
for controlling hormone production and tumor growth,
with its consequential mass-effect on the adjacent brain
structures[9-12].
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delivery-techniques or newer radiation techniques,
a l l o w i n gf o rb e t t e rt a r g e td o s e-conformation, including
but not limited to intensity modulated RT[13], proton
beam therapy[14], radiosurgery[15-17] or stereotactic
fractionated RT (SFRT)[1,18,19]. In this report, we
examined the efficacy and toxicity of SFRT for PMA in
27 patients with long term follow-up treated in an aca-
demic center.
Methods and materials
The institutional database of the departments of Radiation
Oncology of Geneva University Hospital (HUG) and Lau-
sanne University Hospital (CHUV) were queried. Eligibility
criteria for this retrospective analysis were: 1) PMA; 2)
SFRT with definitive intent (patients receiving palliative
radiotherapy were not included in this study) and 3) com-
plete endocrinological, radiological and ophthalmological
follow-up available. Between March 2000 and March
2009, 27 such patients were identified and underwent
SFRT at CHUV, using a linear accelerator dedicated to
stereotactic radiation therapy (Siemens USA, New York,
NY). PMA patients seen at HUG were referred to the
CHUV for SFRT. This retrospective study was approved
by both the CHUV’sa n dH U G ’s Institutional Review
Boards. The medical records of these patients, followed by
the Endocrinology and Ophthalmology departments of
both centers, were reviewed through the most recent fol-
low-up visit with respect to pituitary function, visual func-
tion and radiological changes in tumor volume. The acute
and late toxicity, possibly related to SFRT, was assessed
during routine follow-up in the CHUV and HUG radiation
oncology departments.
Prior to SFRT, all patients were evaluated by a multi-
disciplinary tumor board composed of endocrinologists,
neurosurgeons, neuroradiologists and radiation oncolo-
gists before and after the initiation of therapy.
T h eb a s e l i n ec h a r a c t e r i s tics of the PMA 27 patients
(male, n =1 5 ;f e m a l e ,n = 12) are detailed in Table 1. Med-
ian age was 56.5 years (range, 20.3 - 77.4). Of the 27
patients, 26 with newly diagnosed PMA underwent trans-
sphenoidal surgery (TSS) as initial therapy, with or without
craniotomy (Table 1). Of these patients, 2 and 1 had TSS
followed by craniotomy and TSS followed by a repeated
TSS procedure, respectively. One patient with Cushing dis-
ease did not have surgery, as the PMA was evaluated to be
invasive and thus non-resectable (Table 1) and this patient
underwent radical SFRT. Ten (37%; Table 1) patients had
functional (ACTH, n = 3; prolactin, n =3 ;G H ,n =2 ;
ACTH/GH, n =1a n dG H / P R L ,n =1 )P M Aa n dt h e s e
patients received antisecretory medication during SFRT.
Patients were considered for SFRT if they had visual func-
tion, with or without mass effect on the adjacent optic
apparatus, progressive radiological and/or biological disease
and definable tumor on brain MRI. SFRT was administered
4.2 to 242.6 months after the initial TSS (median, 22.4).
A thermoplastic stereotactic mask (BrainLAB, Feld-
kirchen, Germany) was used for SFRT. Gross tumor
volume (GTV) was delineated in the Brainscan (Ver. 5.21)
treatment planning system, using image fusion from the
CT and MRI datasets. All GTVs and organs at risk (OARs),
including but not limited to the optic apparatus, brainstem
and temporal lobes, were identified and defined by the
same radiation oncologist (AP). The planned target volume
(PTV) was defined as the GTV + 2.5 mm. Isodose prescrip-
tions were based on the isodose volume that most closely
approximated the PTV. Two third (n = 18) of the prescrip-
tion isodose were 100%. Six and 3 patients were treated at
the 85% and 90% isodose line, respectively. The dose con-
straints to the brainstem, eyeball and temporal lobes were
54, 10 and 30 Gy, respectively. The maximum dose to the
optic chiasm and optic nerve was kept below 54 Gy. All
dose constraints were met during SFRT planning.
All patients were treated with 1.8 Gy dose per frac-
tion. Median total administered dose was 50.4 Gy
(range, 45.0 - 54.0). The use of stereotactic conformal
technique provided appropriate coverage of the pre-
scribed dose to the PTV with a median conformity
index of 1.2 (range, 1-1.7).
Table 1 Patient’s and treatment characteristics
No. of patients (%)
Type of PMA
Functional 10 (37.0)
Non-functional 17 (63.0)
Prior surgery
None 1 (3.7)
One 23 (85.2)
Two 3 (11.1)
Type of surgery
TSH
one 23 (85.2)
Two 1 (3.7)
Craniotomy and TSH 2 (7.4)
Prior radiotherapy 0 (0.0)
Visual field defect
No 17 (63.0)
Yes 10 (37.0)
Visual tract and PMA
PMA not abutting visual tract 15 (55.6)
PMA abutting visual tract 3 (11.1)
PMA compressing visual tract 9 (33.3)
Endocrine function
Normal 9 (33.3)
Partial anterior pituitary deficiency 18 (66.7)
Complete anterior pituitary deficiency 0 (0.0)
PMA, Pituitary macroadenoma; TSH, transsphenoidal hypophyectomy.
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After SFRT, patients were followed at 3, 6 and 12 months
in the first year and yearly thereafter for endocrine
workup. Serial brain imaging studies (MRI) were requested
usually at 6 months and 1 year after SFRT, annually for
the next 2 years and one once every second or third year
thereafter. Neuro-ophtalmologic follow up was performed
yearly. Treatment failure was defined as interval growth
demonstrated on serial post-SFRT MRI scans and/or
increase in hormone production. Acute toxicities were
defined as those adverse events that occur from the first
day of the treatment through day 90 after treatment. All
side effects seen after 90 days from the end of SFRT were
considered late complications. Acute and late complica-
tions were classified according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events (CTCAE) v3.0 grading system (http://www.eortc.
be/services/doc/ctc/ctcaev3.pdf), except for the skin
erythema which was scored using the Radiation Therapy
Oncology Group (RTOG) scoring system (http://www.
rtog.org/ResearchAssociates/AdverseEventReporting/
CooperativeGroupCommonToxicityCriteria.aspx). All
patients were followed > 1 year and none were lost to fol-
low-up. The mean follow-up time was 72.4 ± 37.2 months.
Statistical analysis
Adenoma volumes were measured in accordance with the
2000 guidelines to evaluate tumor response[20]. Three
orthogonal diameters were measured from MRI scans
taken before and at intervals after FSRT, and tumor
volume was calculated. Partial response was defined as
tumor shrinkage ≥ 25% and complete response as no visi-
ble tumor. Tumor growth control was calculated from the
date of SFRT using Kaplan-Meier estimates[21]. The
events were local progression or death for treatment fail-
ure. In secreting tumors, the secondary endpoint was the
normalization of hormonal hypersecretion. Biochemical
complete response rate for acromegaly was defined by
basal GH levels < 2.5 ng/ml or glucose-suppressed GH
levels < 1 ng/ml and normal IGF-I values. Normalization
of prolactin hypersecretion was defined as prolactin basal
levels in the normal range for men (3 - 16 ng/ml) and
women (3 - 23 ng/ml). Normalization of Cushing disease
was defined by normal cortisol levels. The actuarial visual
preservation and newly pituitary dysfunction were also
evaluated using the Kaplan-Meier method[21]. In patients
without prior visual compromise, the events for newly
visual toxicity after SFRT was objective visual dysfunction
scores as the uncensored event. Patients considered at risk
of loss of pituitary function after SFRT included patient
with either normal pituitary or hypopituitary function.
Proportions were compared using the Fisher’s exact test
for values ≤ 5. All statistical tests were two sided, with
alpha levels lower than .05 considered statistically
significant. All analyses were performed using the SPSS
statistical package (SPSS 17.0, Chicago, IL; http://www.
spss.com).
Results
All patients were able to complete SFRT. An example of a
treatment is displayed in Figure 1. Mean GTV and PTV
was 2.9 ± 4.6 cm
3 and 8.4 ± 5.8 cm
3, respectively. The
median dose delivered to the optic chiasm and brainstem
was 50 Gy (range, 24.5 - 54.0; mean 47.7 ± 7.3) and 41.0
Gy (range, 13.0 - 52.3; mean, 37.2 ± 12.7), respectively.
Three patients had treatment interruptions (mean, 4.3
days) for technical reasons pertaining to the Linac. Ten
(37%) patients had acute grade 1 - 2 toxicity: 4 patients
presented with grade 1 headache, 3 patients with grade 1 -
2 asthenia (grade 2, n = 1), 2 patients with grade 1 - 2 nau-
sea (grade 2, n = 1) and another patient presented with
transient grade 1 visual compromise. No grade > 2 acute
toxicity was observed. No cranial nerve dysfunction was
observed.
Outcome and Growth control
At last follow-up, all patients were alive. Twenty five
patients presented no radiological tumor progression for
non-functional PMA (n = 15) and no radiological tumor
progression and biological progression for functional PMA
in another 10 patients. Two (7.4%) patients with functional
(ACTH and GH/PRL) macroadenomas presented with
tumor progression, 29.0 and 105.4 months after treatment,
respectively. The estimated tumor growth control was
95.5% [95% CI: 86.9 - 100.0] at 5 years after SFRT (Figure 2).
One patient was salvaged by total hypophysectomy and
another underwent Gamma-knife radiosurgery associated
with octreotide administration.
MRI scans performed after SFRT demonstrated that
the tumor had decrease in size in 6 (22.2%) patients and
remained unchanged for 19 (70.4%) other patients. An
example of tumor shrinkage is depicted in Figure 1.
Visual and endocrine outcome
Before SFRT, patients 18 (66.7%) had decreased pituitary
function and 9 (33.3%) had normal function. Of the latter
group, 2 (22.2%) patient developed new anterior pituitary
deficits. The estimated 5-year survival without new ante-
rior pituitary deficit (Figure 3) was thus 95.8% [95% CI: 87.6
- 100.0]. No patient developed panhypopituitarism.
Of the 27 patients, 12 (44.4%) patients had a tumor
abutting or compressing the optic apparatus (Table 1) and
10 (37.0%) had an objective visual field defect before
SFRT. After this treatment, the visual field had improved
in 5 (50%) patients and remained stable in all others. Of
note, one patient with no visual dysfunction but an abut-
ting tumor on the optic chiasm prior to SFRT developed a
bilateral optic neuropathy 8 months after SFRT, based on
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received a dose of 50.4 Gy with a Dmax for the chiasm of
49.8 Gy and for the optic nerves of 49 Gy. The actuarial 3-
and 5-year vision preservation was thus 95.5% [95% CI:
86.9 - 100.0].
Serial changes for hormonal levels were evaluated in
10 functional PMA. Of these, true biochemical remis-
sion rate occurred in 3 (30%) patients and treatment
failed in 7 (70%) patients. One patient with a GH-secret-
ing PMA had no somatostatin analogs and normal levels
 
Figure 1 Pre- and post-treatment MRI and CT scan with the
dose deposition.
Figure 2 Estimated tumor growth control.
Figure 3 Estimated rate of anterior pituitary function
preservation.
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was observed in two other patients with prolactin- and
ACTH-secreting tumors, respectively. The cumulative
hormone remission rate is illustrated in Figure 4. No
difference in hormone remission was observed in
ACTH-secreting and non-ACTH-secreting PMA was
observed (p = 0.99).
Discussion
The results of this study suggest that SFRT achieves high
(> 95%) local control (Figure 2) for PMA with exceptional
radiation-induced toxicity. The observed tumor control
rates compares favorably with other SFRT series for smal-
ler pituitary tumors[18,19,22-24]. Gamma knife-radiosur-
gery (SRS) has also been administered to patients with
PMA [15,25]. Owing to the biological advantage of a single
fraction of radiation, an increase in objective radiological
response (i.e. 60 - 70%) is usually observed after SRS[16,25]
when compared to SFRT. SRS is usually limited however
to smaller tumors, in vicinity (≥ 2-3 mm) of the optic appa-
ratus but not abutting this critical structure and the radio-
surgery dose constraint for the optic nerve and chiasm is
usually 8 Gy. This dose constraint derives the observed
78% risk of optic neuropathy in patients receiving > 15 Gy,
when compared to 27% when the radiosurgical delivered
dose to the optic apparatus is the range of 10 to 15 Gy[26].
Newly diagnosed pituitary dysfunction after SRS is
reported in 0 - 50% of patients with normal pituitary func-
tion[7,27-30]. This incidence of radiation-induced toxicity
is alleged to be higher than the observed hypopituitarism
rate after FSRT[23], although data support that the SRS-
SFRT toxicity profile is probably comparable[24]; pituitary
dysfunction is likely however to be higher when patients
are followed long term, such as those treated with SRS.
The indication for SRS thus depends on the target volume
and distance to the optic apparatus. If a small adenoma is
not located in vicinity of the chiasm, we would recommend
SRS. Alternatively, a large tumor in immediate proximity to
the chiasm should be treated with SFRT.
In our series, we have observed an absolute improve-
ment of visual field defect and 5-year vision preservation
rate of 50% and 93.3%, respectively. Noteworthy, approxi-
mately one patient out of two had either a tumor abutting
or compressing the optic apparatus (Table 1). These
results may be in keeping with other SFRT series which
reported an improvement of field defect and vision preser-
vation rate of 0 - 40%[1,18] and 93 - 100%[18,22,23],
respectively. Importantly, the choice of keeping the dose
per fraction < 2 Gy in all patients was appropriate, on the
basis of the data from Parsons et al[31]. The tolerance of
the optic apparatus might be lower in patients with pitui-
tary adenomas, as visual toxicity has been observed at
doses as low as 46 Gy[13,32,33]. Using SFRT for dose
escalation, the Thomas Jefferson group has observed two
cases with visual loss at 50 Gy delivered with conventional
fractionation and has consequently decreased the dose per
fraction at 1.8 Gy[18].
Pituitary hormone deficiency is a frequent (30 - 50%)
complication after conventional postoperative RT for
PMA[7]. In our series, a limited number of patients pre-
sented new anterior pituitary deficits after SFRT and the
estimated 5-year survival without new anterior pituitary
deficits is 96% (Figure 3). These results are comparable to
those reported by other SFRT series with smaller pituitary
tumors[18,22,23,34-36]. We have also observed a 30% hor-
monal response rate in the 10 patients with functional
PMAs. This observed response rate is in line with other
series of SFRT for pituitary tumors[19,22,36,37]. Interest-
ingly, one French prospective study reported a hormonal
superior response rate when treated with SFRT only
(62%), when compared to SFRT and surgery (42%)[19].
Conversely, in a retrospective comparison of radiosurgery
and 3D-CRT, the 2- and 4-year hormonal complete remis-
sion rate was regardless of the treatment modality 26.2%
and 76.3%, respectively[38]. The median time to complete
remission was however significantly (p = 0.007) longer in
the non-radiosurgery group (63 months) when compared
to the radiosurgery group (26 months)[38]. The prolonged
time to hormone normalization was also observed with
SFRT (median, 18 months) when compared to radiosur-
gery (median, 8.5 months) in another series[22].
With a mean follow-up period of 6 years, we have not
observed any brain necrosis, cerebrovascular disease or
radiation-induced tumors. During the carcinogenesis per-
iod for the latter complication, there is a latency time
between exposure to radiation and cancer onset of many
decades. A strong disclaimer should thus be made on the
Figure 4 Cumulative hormone remission rate.
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series. The patient must always be informed of this dire
complication, as the estimated 10 - 30 years cumulative
actuarial risk of developing an in-field secondary cancer is
2 - 3%[12,39,40]. Although we did not assess specifically
the cognitive function of our patients, no dementia or
major cognitive impairment was observed during the fol-
low-up period. The effect of radiation on patient’sc o g n i -
tive function is however controversial, as patient with
pituitary adenoma have suboptimal cognition (anterograde
memory[41], verbal memory and executive functioning
deficits[42,43]) when compared to normal controls. A
recent Dutch study compared the cognitive function,
using validated cognitive tests, of adult patients with non-
functioning PMA who underwent transsphenoidal surgery,
with or without RT. Patients treated with radiation did not
show significant cognition scores when compared to those
treated with surgery only, although these results are some-
what controversial[44].
There were several limitations of our study. First, the
study was retrospective in nature and thus lacked data for
certain important variables such as patient’sn e u r o c o g n i -
tive function and Quality of Life. The small sample size of
27 patients limits somehow the generalizability of these
results. This being said, the patient cohort studied was
unselected, treated with the same physicians and the fol-
low-up period, extending to over 10 years, is substantial.
In summary, SFRT achieves effective tumor control in
patients with PMA with a low incidence of visual or endo-
crinological impairment. No cranial nerve dysfunction or
radiation-induced tumors was observed at follow-up.
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